Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 2

Conditions

Lymphoma, B-Cell, Marginal Zone 11Lymphoma, Mantle-Cell 5Lymphoma, Follicular 2Lymphoma 2Recurrence 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hematologic Neoplasms 1

Interventions

Cyclophosphamide 61Rituximab 50fludarabine 34Prednisone 33Doxorubicin 28Biopsy 26Vincristine 25Specimen Handling 22Magnetic Resonance Spectroscopy 20Bendamustine Hydrochloride 19pembrolizumab 16Lenalidomide 16obinutuzumab 14fludarabine phosphate 14Etoposide 14venetoclax 13Tacrolimus 11Mycophenolic Acid 10Melphalan 10Dexamethasone 10zanubrutinib 9ibrutinib 9acalabrutinib 9Radiotherapy 9Gemcitabine 9Cytarabine 9Busulfan 9Whole-Body Irradiation 8Mesna 8Filgrastim 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Lymphoma × orelabrutinib × 1 year × Clear all
NCT07441993 2026-03-02

MZL-IIT-O

Institute of Hematology & Blood Diseases Hospital, China

Phase 2 Recruiting
30 enrolled
Lymphoid

Lymphoma, Lymphoma, B-Cell, Marginal Zone

NCT07206264 2025-10-03

ADAPT-MCL

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
45 enrolled
Lymphoid

Lymphoma, Lymphoma, Mantle-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡